In ABC DLBCL cells, high degree of cooperativity has been reported for combining Ibrutinib with inhibitors targeting the parallel SYK-PI3K-AKT-mTORC pathway that emanates upstream from BTK [4, 23, 24]. Here, AKT1 is linked to diffuse large B-cell lymphoma.